CSPC PHARMA (01093) has announced that the Clevidipine Butyrate Lipid Emulsion Injection (50ml:25mg, 100ml:50mg), developed by the Group, has obtained a drug registration approval document issued by China's National Medical Products Administration. This product is a dihydropyridine calcium channel blocker, classified as a rapid-acting intravenous antihypertensive agent, and is indicated for the treatment of hypertensive patients who are unsuitable for oral medication or for whom oral drug therapy is expected to be ineffective. Compared to commonly used clinical treatments, this product offers the following significant advantages: faster onset of action, enabling rapid, real-time, and precise blood pressure control; greater suitability for patients with abnormal liver or kidney function, as no dose adjustment is required during administration; and it does not require dilution or preparation for use, providing significant benefits for populations at risk of fluid overload. The approval of this product will further enrich the Group's product pipeline in the cardiovascular and cerebrovascular disease treatment sector, enhance the Group's competitiveness in this field, and is expected to address the unmet clinical need for medications targeting hypertensive emergencies.
Comments